TransMedics Group, Inc. (NASDAQ:TMDX) Shares Acquired by Janus Henderson Group PLC

Janus Henderson Group PLC lifted its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 10.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 15,463 shares of the company’s stock after purchasing an additional 1,428 shares during the quarter. Janus Henderson Group PLC’s holdings in TransMedics Group were worth $2,426,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in TMDX. Cetera Advisors LLC acquired a new stake in shares of TransMedics Group in the 1st quarter worth $392,000. Raymond James & Associates increased its position in TransMedics Group by 152.4% during the second quarter. Raymond James & Associates now owns 23,444 shares of the company’s stock worth $3,531,000 after purchasing an additional 14,156 shares during the last quarter. Vaughan Nelson Investment Management L.P. purchased a new position in TransMedics Group during the second quarter worth about $39,862,000. EFG Asset Management North America Corp. grew its stake in shares of TransMedics Group by 12.4% in the 2nd quarter. EFG Asset Management North America Corp. now owns 21,196 shares of the company’s stock valued at $3,191,000 after buying an additional 2,343 shares during the period. Finally, SlateStone Wealth LLC acquired a new stake in shares of TransMedics Group during the 2nd quarter worth approximately $856,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insider Activity at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. The trade was a 12.27 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the completion of the transaction, the insider now directly owns 20,843 shares in the company, valued at $3,089,766.32. This represents a 12.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,042 shares of company stock valued at $3,563,985 in the last three months. 7.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on TMDX shares. Canaccord Genuity Group decreased their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Piper Sandler decreased their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday. TD Cowen cut their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Wednesday. Finally, Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $126.80.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $65.71 on Friday. TransMedics Group, Inc. has a 52 week low of $65.26 and a 52 week high of $177.37. The firm has a 50 day moving average of $98.83 and a two-hundred day moving average of $132.44. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The stock has a market capitalization of $2.21 billion, a PE ratio of 69.90 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). The firm had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company’s revenue was up 63.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.12) EPS. On average, research analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.